What it is
Vitamin B-12 (cobalamin) is a cobalt-containing corrinoid cofactor — the only biologically essential molecule that contains cobalt. Cyanocobalamin (C₆₃H₈₈CoN₁₄O₁₄P, 1,355.37 Da, CAS 68-19-9, PubChem CID 5311498) is the synthetic, stabilized form produced during industrial cyanide-based purification and is the species in most injectable and oral supplement products. Methylcobalamin (C₆₃H₉₁CoN₁₃O₁₄P, 1,344.43 Da, CAS 13422-55-4) and 5'-deoxyadenosylcobalamin are the two physiologically active intracellular coenzymes — cytosolic and mitochondrial, respectively. Hydroxocobalamin (–OH at the upper axial position) is the form preferred for cyanide poisoning because its hydroxyl ligand is exchanged 1:1 with cyanide to form renally excreted cyanocobalamin. The corrin ring — a reduced porphyrin-like tetrapyrrole — coordinates cobalt to four equatorial nitrogens, a lower 5,6-dimethylbenzimidazole nucleotide base, and a variable upper ligand. The cobalt–carbon bond in methyl- and adenosylcobalamin is one of the first organometallic bonds described in biology. Humans cannot synthesize B-12; only certain bacteria and archaea can. Dietary B-12 is absorbed via a sequential three-protein chaperone system: haptocorrin in saliva, intrinsic factor secreted by gastric parietal cells, and the cubam receptor (cubilin + amnionless) at the terminal ileum. Loss of any step — autoimmune parietal-cell destruction (pernicious anemia), gastrectomy, ileal disease, or chronic PPI / metformin exposure — produces malabsorptive deficiency that parenteral or high-dose oral cyanocobalamin bypasses. B-12 is a vitamin, an FDA-approved drug, and a massively marketed supplement simultaneously — a combination that rewards careful indication-level grading.
In plain English
Vitamin B12 (cobalamin) is the only essential nutrient that contains cobalt — a metal element at its core. It exists in several forms: cyanocobalamin is the stable synthetic version used in most injectable products and supplements; methylcobalamin and adenosylcobalamin are the active forms the body uses inside cells; hydroxocobalamin is the form used for cyanide poisoning treatment because it chemically traps cyanide. Your body cannot make B12 — only certain bacteria can. Humans get it from animal foods. To absorb dietary B12, the body uses a three-step escort system: first, proteins in saliva grab it from food; then a protein made by the stomach (intrinsic factor) takes over; finally, a receptor in the last part of the small intestine (the terminal ileum) pulls it into the body. If any step breaks — autoimmune stomach-cell destruction (pernicious anemia), stomach removal, bowel disease, or long-term use of metformin or acid-blocking drugs — absorption fails. Injecting B12 bypasses the whole system and works even when the gut can't absorb it. The key fact about dosing: the body can only absorb about 1.5–2 micrograms per dose through the normal gut route — the system saturates quickly. That's why megadose oral supplements or injections are used to overcome absorption limits.
How it works
- 01
Methionine synthase and the methylation cycle
Methylcobalamin is the required cofactor for methionine synthase (MTR), the cytosolic enzyme that transfers a methyl group from 5-methyl-tetrahydrofolate to homocysteine, regenerating methionine and tetrahydrofolate. This reaction is the only route for salvaging methyl-THF in humans; without functional methionine synthase, 5-methyl-THF is kinetically trapped (the Herbert 'methyl trap' hypothesis first articulated in Shane & Stokstad 1985 Annu Rev Nutr) and cellular pools of other folates collapse, producing the megaloblastic anemia of B12 deficiency. Methionine produced by this cycle is activated to S-adenosylmethionine (SAM), the universal methyl donor for more than 200 methyltransferase reactions including DNA cytosine methylation, histone methylation, phospholipid head-group methylation, and catecholamine and melatonin biosynthesis. Disruption raises plasma total homocysteine — the more specific biomarker than serum B12 itself for functional cobalamin status (Savage 1994 Am J Med; Stabler 2013 NEJM).
In plain English
How B-12 drives one of the body's core chemical reactions
One form of B-12 (methylcobalamin) is required for an enzyme that converts a waste product called homocysteine into a useful amino acid (methionine) — and in doing so, recycles a critical folate molecule. Without working B-12, the folate gets stuck in a dead-end form the cell can't use. Result: the cell can't make new DNA properly, red blood cells grow oversized and dysfunctional, and homocysteine builds up in the blood. Elevated homocysteine is one of the two key lab markers of B-12 deficiency.
- 02
Methylmalonyl-CoA mutase and the propionate pathway
5'-Deoxyadenosylcobalamin is the required cofactor for methylmalonyl-CoA mutase (MMUT) in the mitochondrial matrix, which isomerizes L-methylmalonyl-CoA (derived from propionyl-CoA from odd-chain fatty acids, branched-chain amino acids, cholesterol side-chain, and thymine catabolism) to succinyl-CoA for entry into the TCA cycle. In B12 deficiency, methylmalonyl-CoA accumulates, is hydrolyzed to methylmalonic acid (MMA), and spills into plasma and urine — the basis for MMA as the most specific biochemical marker of functional B12 deficiency (Allen 1990; Savage 1994). Accumulating propionyl-CoA is incorporated into neuronal membrane lipids as odd-chain and branched fatty acids, a proposed mechanism for the demyelination seen in subacute combined degeneration of the spinal cord — though the myelination story is mechanistically more complex than the early propionate-incorporation model suggested.
In plain English
How B-12 keeps a toxic fat byproduct from building up
Another form of B-12 (adenosylcobalamin) is required for a mitochondrial enzyme that processes a compound made when you break down certain fats and amino acids. Without it, methylmalonic acid builds up and spills into blood and urine — the most specific lab marker for B-12 deficiency. When methylmalonic acid accumulates in nerve tissue, it may contribute to the nerve-sheath damage seen in prolonged B-12 deficiency, causing the numbness and spinal-cord problems that characterize severe deficiency.
- 03
Hydroxocobalamin as a cyanide chelator
The FDA-approved cyanide antidote Cyanokit (hydroxocobalamin 5 g IV, NDA 022041, 2006) works by direct stoichiometric chelation: the hydroxyl upper ligand of hydroxocobalamin is displaced by cyanide, forming non-toxic cyanocobalamin that is renally excreted. The reaction is fast (Borron 2007 Ann Emerg Med documented survival in severe smoke-inhalation cyanide toxicity), does not depend on intact methemoglobin-forming capacity (unlike the older nitrite antidote), and is first-line in pre-hospital and emergency-department cyanide-poisoning protocols. Expected pharmacologic effects include transient hypertension, red discoloration of plasma and urine (which interferes with several colorimetric lab assays), and photosensitivity-like skin flush — all clinically predictable from the mechanism.
In plain English
How the Cyanokit antidote works
Cyanide poisoning (from smoke inhalation or industrial accidents) blocks the energy machinery inside every cell. Hydroxocobalamin — the form in Cyanokit — grabs cyanide molecules directly in a one-to-one exchange, forming an inert compound (cyanocobalamin) that the kidneys filter out. It works fast and doesn't need intermediate steps like older antidotes. FDA-approved 2006. Expected side effects: temporary red discoloration of urine and skin — predictable from the mechanism and harmless.
- 04
Three-protein gut absorption and why parenteral bypass works
Dietary cobalamin is released from food protein by gastric acid and pepsin, bound by haptocorrin (R-binder) in saliva, handed off to intrinsic factor (IF) secreted by gastric parietal cells after pancreatic proteases digest haptocorrin in the duodenum, and absorbed at the terminal ileum by the cubam receptor complex (cubilin + amnionless) (Nielsen 2012 Nat Rev Gastroenterol Hepatol). Only ~50% of a physiological dose is absorbed even in a healthy adult; the system is saturable at a single-dose ceiling of ~1.5–2 mcg via the IF/cubam route. A small fraction (~1%) is absorbed by passive diffusion across the entire small intestine, which is the pharmacologic basis for oral high-dose (1,000–2,000 mcg/day) supplementation as an alternative to parenteral therapy in pernicious anemia (Kuzminski 1998 Blood RCT; Vidal-Alaball 2005 Cochrane review). Parenteral cyanocobalamin entirely bypasses the three-protein absorption chain, which is why it is reliably effective even when IF is absent or the terminal ileum is resected.
In plain English
Why injections work when the gut can't absorb B-12
Absorbing B-12 from food requires three proteins in sequence — one in saliva, one from the stomach, and a receptor in the small intestine. Each step is a potential failure point. Pernicious anemia destroys the stomach protein (intrinsic factor); a removed stomach or diseased intestine breaks other steps. Even in a healthy gut, the system caps out at about 1.5–2 micrograms per meal. Injections bypass the entire chain and absorb at 100%. High-dose oral B-12 (1,000–2,000 mcg daily) also works — because a tiny fraction (~1%) slips through by simple diffusion, and at high enough doses that trickle adds up.
- 05
Pharmacokinetics of parenteral cyanocobalamin
Intramuscular cyanocobalamin 1000 mcg produces peak plasma concentration within ~1 hour (Cyanocobalamin Injection USP Prescribing Information). Bioavailability by IM or SC route is effectively 100%. Plasma B-12 is transported bound to transcobalamin II (the delivery fraction, ~20%) and haptocorrin (the storage fraction, ~80%) — a distinction that the 2025 Beaudry-Richard / Green et al. Ann Neurol paper argues carries independent biological meaning for CNS injury biomarkers even within the 'normal' total-B12 range. 50–98% of a 1000 mcg parenteral dose is excreted unchanged in urine within 48 hours, the bulk within the first 8 hours; this urinary loss is why monthly rather than weekly maintenance dosing is sufficient once hepatic stores (typically 2–5 mg, supporting 3–5 years of requirements) are replete.
In plain English
What happens after a B-12 injection
An intramuscular B-12 injection (1,000 micrograms) peaks in the blood within about an hour. The body absorbs essentially all of it. Most of the dose — up to 98% — is flushed out through the kidneys within 48 hours. The liver stores 2–5 milligrams as a backup reserve that lasts 3–5 years, which is why monthly maintenance shots are sufficient once stores are replenished. Two proteins carry B-12 in the blood: one actively delivers it to cells (~20%), the other holds the reserve (~80%).
- 06
Why the mechanism does not support 'energy' claims in replete patients
Every mechanistic step above — methionine synthase activity, methylmalonyl-CoA mutase activity, methylation capacity, myelin maintenance, erythropoiesis — is saturable. In a B12-replete patient, methionine synthase is operating at Vmax and exogenous cyanocobalamin cannot accelerate it further. There is no enzymatic deficit to rescue, no biosynthetic bottleneck to relieve. This is the mechanistic reason the Almohammed 2020 PLOS ONE placebo-controlled RCT in fatigued but replete adults was negative on FACIT-Fatigue — and the reason additional controlled trials in this population are not forthcoming. The 'B-12 shot for energy' claim requires either an undiagnosed deficiency (in which case the diagnosis, not the shot, is the intervention) or a placebo response. Both happen. Neither is a pharmacologic mechanism.
In plain English
Why B-12 shots don't give non-deficient people more energy
Every enzyme that uses B-12 is already running at maximum speed in a person with normal B-12 levels. Adding more B-12 is like pouring extra gasoline into a tank that's already full — the engine doesn't go faster. A placebo-controlled trial (Almohammed 2020) tested this: 60 fatigued adults with normal B-12 got either a weekly B-12 injection or saline for three weeks. No difference in fatigue scores. The energy boost some wellness-clinic patients report is either a placebo response or reflects an undiagnosed deficiency — which is a diagnosis problem, not a pharmacology boost.